TriSalus Reports Q1 2024 Financial Results and Business Update May 15, 2024 08:00AM
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors May 7, 2024 07:00AM
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call May 6, 2024 04:58PM
TriSalus Life Sciences (TLSI) Secures $50M Debt Financing with OrbiMed Apr 30, 2024 04:36PM
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives Apr 30, 2024 04:35PM


Apr 1, 2024 08:00AM TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
Mar 26, 2024 08:00AM TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting
Mar 21, 2024 08:00AM TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
Mar 11, 2024 05:15PM TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results
Mar 7, 2024 07:00AM TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-1
Feb 29, 2024 07:00AM TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors
Dec 14, 2023 07:00AM TriSalus Life Sciences Announces CMS Reimbursement for the TriNav® Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code
Nov 14, 2023 08:00AM TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 7, 2023 04:05PM TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call
Nov 4, 2023 02:25PM Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications
Nov 3, 2023 12:00PM TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oct 25, 2023 09:05AM TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Sep 6, 2023 07:00AM TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics
Aug 10, 2023 04:05PM TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation
Nov 14, 2022 07:17AM TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition Corporation (MTAC)
Nov 14, 2022 07:00AM TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition Corporation